The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients

There are many active drugs to treat metastatic renal cell carcinoma (mRCC) patients who progress through their first-line vascular endothelial growth factor (VEGF) inhibitor. Many clinicians choose a second-line VEGF inhibitor based on the type of response to first-line VEGF inhibitor, without data...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Al-Marrawi, Mhd Y., Rini, Brian I., Harshman, Lauren C., Bjarnason, Georg, Wood, Lori, Vaishampayan, Ulka, MacKenzie, Mary, Knox, Jennifer J., Agarwal, Neeraj, Al-Harbi, Hulayel, Kollmannsberger, Christian, Tan, Min-Han, Rha, Sun Young, Donskov, Frede N., North, Scott, Choueiri, Toni K., Heng, Daniel Y.
Format: Artigo
Idioma:Inglês
Publicat: 2013
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4144038/
https://ncbi.nlm.nih.gov/pubmed/23300029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11523-012-0252-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars